KYG2646Y1044
KYG2646Y1044
Damora Therapeutics, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | -- | -- | -- |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| 210.872.000 | 21.292.000 | 890.4% | |
| Operating Income | -210.872.000 | -21.292.000 | 890.4% |
| Pretax Income | -209.789.000 | -21.398.000 | 880.4% |
| Net Income Common Stockholders | -209.839.000 | -21.439.000 | 878.8% |
| -- | -- | -- | |
| -- | -- | -- |